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1. Introduction
Cure is only possible in hepatocellular carcinoma (HCC)
when all cancer cells have been ablated using a single
or multi-modality treatment. Unresectable HCC is by
deﬁnition advanced and the chance of cure is remote. At
this stage, local ablative therapy or liver transplantation
is no longer an option. The aim of treatment is palliative,
mainly to minimise symptoms and to prolong life.
Improvements in locoregional and systemic treatment
can convert advanced to earlier-stage HCC and from non-
curable to potentially curable disease. This downstaging
of tumours differs fundamentally from neoadjuvant
therapy which is used to treat patients with curable
disease in order to improve the duration of survival after
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resection. After tumour downstaging in advanced HCC,
salvage surgery (either in the form of partial hepatec-
tomy or liver transplantation) is required as complete
histological tumour necrosis occurs in only a minority
of patients. Studies on tumour downstaging show that
neither normalisation of serum alpha fetoprotein nor
complete radiological tumour response correlates with
the absence of viable tumour cells detected in specimens
obtained after salvage liver resection. 1
The reasons why HCC becomes resectable or trans-
plantable after tumour downstaging are: the disappear-
ance of either intrahepatic or extrahepatic tumours,
shrinkage of tumours, disappearance of portal venous
tumour thrombi, and/or hypertrophy of non-tumourous
part of the liver.
The pre-requisites for a successful downstaging
programme are: the availability of an effective treatment
for downstaging, close monitoring of the results of down-
staging, an experienced liver surgeon who repeatedly re-
evaluates tumour resectability/transplantability and an
aggressive surgical approach adopted in treatment of
these patients.
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2. Selective internal radiation therapy
Tumour downstaging using yttrium-90 (90Y) micro-
spheres has been reported in 0.7−5.6% of patients
with unresectable HCC which becomes resectable, 2−4
and in 11−23% of patients with untransplantable
HCC which becomes transplantable. 2,3 The higher liver
transplantation rates are a consequence of the improved
liver function after surgery while the reverse is true
for liver resection. Selective internal radiation ther-
apy (SIRT) with 90Y-microspheres can also be combined
with systemic chemotherapy in order to downstage
unresectable to resectable HCC. 2 Salvage liver resection
following downstaging with 90Y-microspheres resulted in
a 1-year survival of 84% and a 3-year survival of 27% 3
with better results were reported by other authors. 2
The interval between SIRT and salvage liver resection
should be at least 8 months in order to ensure adequate
tumour shrinkage and hypertrophy of the non-tumorous
liver and to allow sufﬁcient time for the non-tumorous
liver to recover from the effects of SIRT.
The situation for liver transplantation is more com-
plex and involves consideration of the best use of
donor organs and resources. If the HCC has been
downstaged to within the Milan criteria and with a
serum alpha fetoprotein <400ng/mL, the outcomes are
broadly equivalent to patients who were ﬁrst selected
for liver transplantation based on the same criteria. 5
Most surgeons agree that a minimum interval of
6 months between downstaging and transplantation is
essential to identify and exclude patients with rapid
tumour regrowth, metastases or portal venous invasion
with thrombi. Good results with liver transplantation
after downstaging with 90Y-microspheres have been
reported 3,6,7 and even for HCC involving the caudate lobe.
In a non-randomised study, 90Y-microspheres were more
effective than transarterial chemoembolisation (TACE) in
shrinking T3 HCC to transplantable T2 HCC. 6 Overall,
SIRT using 90Y-microspheres appears to be well tolerated
with no reported harmful effects on arterial or vascular
anastomosis in liver transplantation.
The safety proﬁle of 90Y microspheres also means that
SIRT can be used as bridging therapy to extend the time
to patients waiting for a liver donor without affecting
post-transplant survival. 8
Riaz et al. (2009) recently suggested that radiation
lobectomy/segmentectomy may improve the safety of
SIRT, 9 although more data are needed to determine
whether these techniques will increase the numbers of
patients with unresectable HCC who are downstaged to
resectable or transplantable HCC.
3. Conclusion
Downstaging HCC from unresectable to resectable and
non-transplantable to transplantable using 90Y-micro-
spheres is possible with prospective of cure for some
patients who previously were considered as non-
curable.
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